{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10072","date":"2022-03-02T21:42:59.231Z","role":"Publisher"},{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10072","date":"2021-10-07T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:c5042e46-017f-47a4-8989-d857868ae565","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:41341fbf-fd03-4c38-9e14-9cdc41f79789","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"Immunohistochemistry in adult wildtype mice indicates that ATF6 is expressed in the ganglion cell layer, inner nuclear layer, and outer nuclear layer of the retina","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26070061","type":"dc:BibliographicResource","dc:abstract":"Photoreceptor degeneration (PRD) is a genetically heterogeneous retinal disorder. Although a number of genes involved in PRD have been identified, their genetic basis remains unknown in a significant number of patients. In this study, we aimed to identify novel disease-causing genes of PRD.","dc:creator":"Xu M","dc:date":"2015","dc:title":"ATF6 Is Mutated in Early Onset Photoreceptor Degeneration With Macular Involvement."},"rdfs:label":"Western blotting - expression in mice"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:39db43e2-37b3-4d8a-8316-41f4c9007817","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:910bfaf9-9763-42f3-9b69-f0b6a7f195bd","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"RT-PCR performed on commercially obtained RNA samples showed expression of three known ATF6 isoforms in human eye, particularly in the RPE cells. Western blot analysis using anti-ATF6 antibodies on protein extract from adult C57BL/6J mouse retina (Fig S3e). Immunofluorescent staining of CD1 mouse retinae revealed that ATF6 immunoreactivity is most prominent in the retinal ganglion cells. Staining was also observed in the retinal pigment epitheleum, outer and inner segments of photoreceptor cells, inner and outer plexiform layers, as well as in the inner nuclear layer of neuronal retina (Fig 2 - top, p946, S5).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26063662","type":"dc:BibliographicResource","dc:abstract":"Achromatopsia (ACHM) is an early-onset retinal dystrophy characterized by photophobia, nystagmus, color blindness and severely reduced visual acuity. Currently mutations in five genes CNGA3, CNGB3, GNAT2, PDE6C and PDE6H have been implicated in ACHM. We performed homozygosity mapping and linkage analysis in a consanguineous Pakistani ACHM family and mapped the locus to a 15.12-Mb region on chromosome 1q23.1-q24.3 with a maximum LOD score of 3.6. A DNA sample from an affected family member underwent exome sequencing. Within the ATF6 gene, a single-base insertion variant c.355_356dupG (p.Glu119Glyfs*8) was identified, which completely segregates with the ACHM phenotype within the family. The frameshift variant was absent in public variant databases, in 130 exomes from unrelated Pakistani individuals, and in 235 ethnically matched controls. The variant is predicted to result in a truncated protein that lacks the DNA binding and transmembrane domains and therefore affects the function of ATF6 as a transcription factor that initiates the unfolded protein response during endoplasmic reticulum (ER) stress. Immunolabeling with anti-ATF6 antibodies showed localization throughout the mouse neuronal retina, including retinal pigment epithelium, photoreceptor cells, inner nuclear layer, inner and outer plexiform layers, with a more prominent signal in retinal ganglion cells. In contrast to cytoplasmic expression of wild-type protein, in heterologous cells ATF6 protein with the p.Glu119Glyfs*8 variant is mainly confined to the nucleus. Our results imply that response to ER stress as mediated by the ATF6 pathway is essential for color vision in humans.","dc:creator":"Ansar M","dc:date":"2015","dc:title":"Mutation of ATF6 causes autosomal recessive achromatopsia."},"rdfs:label":"RT-PCR, Western, and immunolocalization"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:0bc2ac97-defc-4028-a6c2-dd51b2832cf5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:bedc7aa3-d5d7-42a6-9d90-ed29caefd654","type":"FunctionalAlteration","dc:description":"Transfected HEK293 cells with DHFR fusion constructs for WT or p.Arg324Cys ATF (described above). Confirmed expression by Western blot. HSPA5 mRNA (which is highly induced by ATF6; encodes GRP78, also known as BiP, protein) and GRP78 (BiP) protein levels were significantly induced in cells expressing WT AFT6, after addition of trimethorprim. In contrast, HSPA5 mRNA and GRP78 (BiP) protein levels were NOT significantly induced in cells expressing p.Arg324Cys ATF. Demonstrates that ATF6 encoding p.Arg324Cys comprmises AFT6A transcriptional activity.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26029869","type":"dc:BibliographicResource","dc:abstract":"Achromatopsia (ACHM) is an autosomal recessive disorder characterized by color blindness, photophobia, nystagmus and severely reduced visual acuity. Using homozygosity mapping and whole-exome and candidate gene sequencing, we identified ten families carrying six homozygous and two compound-heterozygous mutations in the ATF6 gene (encoding activating transcription factor 6A), a key regulator of the unfolded protein response (UPR) and cellular endoplasmic reticulum (ER) homeostasis. Patients had evidence of foveal hypoplasia and disruption of the cone photoreceptor layer. The ACHM-associated ATF6 mutations attenuate ATF6 transcriptional activity in response to ER stress. Atf6(-/-) mice have normal retinal morphology and function at a young age but develop rod and cone dysfunction with increasing age. This new ACHM-related gene suggests a crucial and unexpected role for ATF6A in human foveal development and cone function and adds to the list of genes that, despite ubiquitous expression, when mutated can result in an isolated retinal photoreceptor phenotype.","dc:creator":"Kohl S","dc:date":"2015","dc:title":"Mutations in the unfolded protein response regulator ATF6 cause the cone dysfunction disorder achromatopsia."},"rdfs:label":"Transcriptional activity of DHFR-ATF6 fusion proteins"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:e6e566c8-0230-4178-afc4-3945b85527af","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:ccf04394-f1e2-4cbc-aa68-e9828778d881","type":"FunctionalAlteration","dc:description":"Confocal imaging of the tagged WT ATF6 revealed expression throughout the cytoplasm and localization to the ER. Mutant ATF6 (p.Glu119Glyfs*8; identified in affected members of family) had significantly reduced localization in the cytoplasm and was mainly confined to the nucleus.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26063662","rdfs:label":"Localization of mutant protein in COS cells"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:12f1c210-8ca8-4e0c-9394-fce2651192be","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c49fde88-a17d-411a-bca2-79ac14256e45","type":"FunctionalAlteration","dc:description":"qRT-PCR and RNA-Seq analyses demonstrated that transcriptional activity was lost for the mutants. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/32271167","type":"dc:BibliographicResource","dc:abstract":"Achromatopsia (ACHM) is an autosomal recessive disease that results in severe visual loss. Symptoms of ACHM include impaired visual acuity, nystagmus, and photoaversion starting from infancy; furthermore, ACHM is associated with bilateral foveal hypoplasia and absent or severely reduced cone photoreceptor function on electroretinography. Here, we performed genetic sequencing in 3 patients from 2 families with ACHM, identifying and functionally characterizing 2 mutations in the activating transcription factor 6 (ATF6) gene. We identified a homozygous deletion covering exons 8-14 of the ATF6 gene from 2 siblings from the same family. In another patient from a different family, we identified a heterozygous deletion covering exons 2 and 3 of the ATF6 gene found in trans with a previously identified ATF6 c.970C>T (p.Arg324Cys) ACHM disease allele. Recombinant ATF6 proteins bearing these exon deletions showed markedly impaired transcriptional activity by qPCR and RNA-Seq analysis compared with WT-ATF6. Finally, RNAscope revealed that ATF6 and the related ATF6B transcripts were expressed in cones as well as in all retinal layers in normal human retina. Overall, our data identify loss-of-function ATF6 disease alleles that cause human foveal disease.","dc:creator":"Lee EJ","dc:date":"2020","dc:title":"Multiexon deletion alleles of ATF6 linked to achromatopsia."},"rdfs:label":"RNA-Seq analysis"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:d48a6815-e120-4e7f-98dc-848b2bc7ce68","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:7af1b320-031c-4045-9a19-f68aeb0a158f","type":"FunctionalAlteration","dc:description":"Class 1 variant Impairs ER-to-Golgi Trafficking During ER Stress. Constitutive Transcriptional Activity in Class 2 ATF6 Mutants however expected to undergo nonsense mediated decay. Class 3 ATF6 Mutants Are Transcriptionally Inactive. Class 1 and 3 variants are susceptible to ER Stress-Mediated Cell Death.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28028229","type":"dc:BibliographicResource","dc:abstract":"Achromatopsia is an autosomal recessive disorder characterized by cone photoreceptor dysfunction. We recently identified activating transcription factor 6 (ATF6) as a genetic cause of achromatopsia. ATF6 is a key regulator of the unfolded protein response. In response to endoplasmic reticulum (ER) stress, ATF6 migrates from the ER to Golgi to undergo regulated intramembrane proteolysis to release a cytosolic domain containing a basic leucine zipper (bZIP) transcriptional activator. The cleaved ATF6 fragment migrates to the nucleus to transcriptionally up-regulate protein-folding enzymes and chaperones. ATF6 mutations in patients with achromatopsia include missense, nonsense, splice site, and single-nucleotide deletion or duplication changes found across the entire gene. Here, we comprehensively tested the function of achromatopsia-associated ATF6 mutations and found that they group into three distinct molecular pathomechanisms: class 1 ATF6 mutants show impaired ER-to-Golgi trafficking and diminished regulated intramembrane proteolysis and transcriptional activity; class 2 ATF6 mutants bear the entire ATF6 cytosolic domain with fully intact transcriptional activity and constitutive induction of downstream target genes, even in the absence of ER stress; and class 3 ATF6 mutants have complete loss of transcriptional activity because of absent or defective bZIP domains. Primary fibroblasts from patients with class 1 or class 3 ATF6 mutations show increased cell death in response to ER stress. Our findings reveal that human ATF6 mutations interrupt distinct sequential steps of the ATF6 activation mechanism. We suggest that increased susceptibility to ER stress-induced damage during retinal development underlies the pathology of achromatopsia in patients with ATF6 mutations.","dc:creator":"Chiang WC","dc:date":"2017","dc:title":"Achromatopsia mutations target sequential steps of ATF6 activation."},"rdfs:label":"Transcriptional activity in fibroblasts"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"cggv:8dfcc6ad-26d9-46d8-9965-0b3f5cc40cac","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:42a27f26-00c5-4eb4-9bdf-d8246d4f236b","type":"FunctionalAlteration","dc:description":"Exposed fibroblasts to tunicamycin, an inhibitor of N-linked glycosylation that causes protein misfolding in the ER and potently activates ATF6A. All patient-derived fibroblasts homozygous for p.Arg324Cys showed significantlty reduced HSPA5 mRNA (one of the most highly induced transcriptional targets of ATF6; encodes GRP98, also known as BiP) and GRP78 (BiP) prorein induction after tunicamyin exposure, in comparison with fibroblasts from heterozygous mother.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869","rdfs:label":"Effect of p.Arg324Cys on ATF6 transcriptional activity"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:49bbb246-e9bd-4225-bd14-e5f74f306019","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:380b5e5a-7353-4d40-8ae1-65e12256267a","type":"Finding","demonstrates":{"id":"cg:PhenotypeRescue"},"dc:description":"AA147 potently rescues the transcriptional function of the Y567N in vitro","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/34561305","type":"dc:BibliographicResource","dc:abstract":"Endoplasmic reticulum (ER) stress and Unfolded Protein Response (UPR) signaling promote the pathology of many human diseases. Loss-of-function variants of the UPR regulator ","dc:creator":"Kroeger H","dc:date":"2021","dc:title":"ATF6 is essential for human cone photoreceptor development."},"rdfs:label":"Small molecule rescue"}],"specifiedBy":"GeneValidityCellCultureRescueCriteria","strengthScore":0.5,"dc:description":"Retina GCEP opted to half score "},{"id":"cggv:7d76f4e1-caea-4172-97a6-be596355e017","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:ab8e0915-f79d-4806-9c70-577bf7e4a358","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Humans have absent/impaired photopic (cone) responses on ERG, which aligns with the abnormal cone photoreceptors in retinal organoids","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34561305","rdfs:label":"Retinal organoids"}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":0.5,"dc:description":"Half score because the changes observed are not clearly demonstrated to be due to ATF6 "},{"id":"cggv:56d94666-a30a-4cc0-bfce-be21555d02ad","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:88fc1db0-7dba-4520-ba82-c215fbf74668","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Functional deficits in photoreceptor cells. As in patients, retinal vasculature appeared unaffected in mouse model.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869","rdfs:label":"Atf6 KO mice"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"Phenotype of Atf6 knock out mice does not completely recapitulate the features of human achromatopsia. Specifically, alterations in photoreceptor function are only seen at an older age in mice."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5},{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:f9bd9611-3fb1-4d23-9043-d982cf07478b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f9bd9611-3fb1-4d23-9043-d982cf07478b","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":25,"allele":{"id":"cggv:377e94f9-df1e-4f4e-8af7-42162edd9349","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.1699T>A (p.Tyr567Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA214892"}},"phenotypes":"obo:HP_0007750","sex":"Female","variant":{"id":"cggv:b7add843-3210-435c-ad67-deb17f1862e7_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:377e94f9-df1e-4f4e-8af7-42162edd9349"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31237654","type":"dc:BibliographicResource","dc:abstract":"Mutations in six genes have been associated with achromatopsia (ACHM): CNGA3, CNGB3, PDE6H, PDE6C, GNAT2, and ATF6. ATF6 is the most recent gene to be identified, though thorough phenotyping of this genetic subtype is lacking. Here, we sought to test the hypothesis that ATF6-associated ACHM is a structurally distinct form of congenital ACHM.","dc:creator":"Mastey RR","dc:date":"2019","dc:title":"Characterization of Retinal Structure in ATF6-Associated Achromatopsia."}},"rdfs:label":"AV_10962"},{"id":"cggv:b7add843-3210-435c-ad67-deb17f1862e7","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:b7add843-3210-435c-ad67-deb17f1862e7_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:a1878b09-4ff1-4762-9e76-8e2351f3e864_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:a1878b09-4ff1-4762-9e76-8e2351f3e864","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":32,"allele":{"id":"cggv:b6ce1edd-f366-442d-8269-c949430d076a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.1533+1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA346964"}},"detectionMethod":"The article states \".....whole exome sequencing and candidate gene screening...\" but does not elaborate on whether both approaches were used in all families, or WES for some and candidate gene screening for others.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"sex":"Male","variant":{"id":"cggv:68435462-df86-4b89-9e27-aefe20483ade_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b6ce1edd-f366-442d-8269-c949430d076a"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"},"rdfs:label":"MOGL5414- II.1"},{"id":"cggv:68435462-df86-4b89-9e27-aefe20483ade","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:68435462-df86-4b89-9e27-aefe20483ade_variant_evidence_item"}],"strengthScore":1,"dc:description":"Down-scored because homozygous variant and no functional data provided in this paper. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:1ee0e05f-9883-4786-b9df-ce6ad18d2a90_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:1ee0e05f-9883-4786-b9df-ce6ad18d2a90","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":16,"allele":{"id":"cggv:3c79d57b-03b4-4d9c-8e0c-56b4b0455b5b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.355dup (p.Glu119GlyfsTer8)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575758"}},"detectionMethod":"Homozygosity and linkage analysis identified a 15.12Mb critical region. WES was performed in Individual III.1; WES data were analyzed to find variants within the critical region that were not in dbSNP and had a MAF of <0.05%.","firstTestingMethod":"Exome sequencing","previousTestingDescription":"No previous testing described.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:6792b11b-8ecc-4c84-a8c0-aede7fae5360_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:3c79d57b-03b4-4d9c-8e0c-56b4b0455b5b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26063662"},"rdfs:label":"Individual III.1"},{"id":"cggv:6792b11b-8ecc-4c84-a8c0-aede7fae5360","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:6792b11b-8ecc-4c84-a8c0-aede7fae5360_variant_evidence_item"},{"id":"cggv:6792b11b-8ecc-4c84-a8c0-aede7fae5360_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"p. 947  \"in vitro, the p.Glu119Glyfs*8 variant affects the targeting and\nlocalization of ATF6.\""}],"strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:9edc00e5-d41b-426e-b015-fbc28f2c8d72_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:9edc00e5-d41b-426e-b015-fbc28f2c8d72","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"allele":{"id":"cggv:f4ab63cd-681b-4bbd-a962-54b5d3e3c78d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.970C>T (p.Arg324Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA346915"}},"phenotypes":"obo:HP_0007750","sex":"Male","variant":{"id":"cggv:a49a4b8b-c9ef-4764-a914-563f4a730473_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:f4ab63cd-681b-4bbd-a962-54b5d3e3c78d"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/31237654"},"rdfs:label":"TM_11446"},{"id":"cggv:a49a4b8b-c9ef-4764-a914-563f4a730473","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:a49a4b8b-c9ef-4764-a914-563f4a730473_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:db999481-c495-476d-9f3c-39a92056b160_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:db999481-c495-476d-9f3c-39a92056b160","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":41,"allele":{"id":"cggv:c01c921c-ec8f-49f6-8f38-c6e1d8472db2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.353del (p.Pro118LeufsTer31)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/209097"}},"detectionMethod":"The article states \".....whole exome sequencing and candidate gene screening...\" but does not elaborate on whether both approaches were used in all families, or WES for some and candidate gene screening for others.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"sex":"Female","variant":{"id":"cggv:68ac7afe-f623-47b2-a9b8-81629875197a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c01c921c-ec8f-49f6-8f38-c6e1d8472db2"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"},"rdfs:label":"ZD179- II.1"},{"id":"cggv:68ac7afe-f623-47b2-a9b8-81629875197a","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:68ac7afe-f623-47b2-a9b8-81629875197a_variant_evidence_item"}],"strengthScore":1,"dc:description":"Down-scored because homozygous variant with no additional functional evidence provided in paper. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f84988c0-decb-432e-8300-0fcf6f0ea7f6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f84988c0-decb-432e-8300-0fcf6f0ea7f6","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":47,"allele":{"id":"cggv:f4ab63cd-681b-4bbd-a962-54b5d3e3c78d"},"phenotypeFreeText":"Relative central scotoma.","phenotypes":"obo:HP_0007761","sex":"Female","variant":{"id":"cggv:85858e10-a32b-4788-a344-7a7cf1d3a84a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:f4ab63cd-681b-4bbd-a962-54b5d3e3c78d"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"},"rdfs:label":"CHRO91 II:1"},{"id":"cggv:85858e10-a32b-4788-a344-7a7cf1d3a84a","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:85858e10-a32b-4788-a344-7a7cf1d3a84a_variant_evidence_item"},{"id":"cggv:85858e10-a32b-4788-a344-7a7cf1d3a84a_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Patient-derived fibroblasts homozygous for p.Arg324Cys had defective ATF6 transcriptional activity. "}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:955153b4-cdbd-434b-887b-6ae843bd3a34_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:955153b4-cdbd-434b-887b-6ae843bd3a34","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":17,"allele":{"id":"cggv:b6ce1edd-f366-442d-8269-c949430d076a"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"sex":"Male","variant":{"id":"cggv:6b0aca30-5dd1-4c12-87e2-ecd980e0c294_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b6ce1edd-f366-442d-8269-c949430d076a"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"},"rdfs:label":"CHRO593 IV:1"},{"id":"cggv:6b0aca30-5dd1-4c12-87e2-ecd980e0c294","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:6b0aca30-5dd1-4c12-87e2-ecd980e0c294_variant_evidence_item"}],"strengthScore":1,"dc:description":"Down-scored due to homozygous variant with no functional data provided in this paper."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:58e0c5dd-c99e-4794-b063-d1bc81b44b72_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:58e0c5dd-c99e-4794-b063-d1bc81b44b72","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":26,"allele":{"id":"cggv:377e94f9-df1e-4f4e-8af7-42162edd9349"},"detectionMethod":"The article states \".....whole exome sequencing and candidate gene screening...\" but does not elaborate on whether both approaches were used in all families, or WES for some and candidate gene screening for others.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Relative central scotoma. Bilateral sensorineural hearing loss, diagnosed at 1 year of age, hypothyroidism since childhood, celiac disease. Of note, her elder sister (CHRO649 II:2) also had bilateral sensorineural HL but normal eye exam and is heterozygous for p.Tyr567Asn, suggesting that the HL in the proband with achromatopsia is unrelated to homozygosity for ATF6 mutations.","phenotypes":"obo:HP_0007761","sex":"Female","variant":{"id":"cggv:3466ae8c-33f0-4aa0-ad9e-65db4f040432_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:377e94f9-df1e-4f4e-8af7-42162edd9349"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"},"rdfs:label":"CHRO649- II:1"},{"id":"cggv:3466ae8c-33f0-4aa0-ad9e-65db4f040432","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:3466ae8c-33f0-4aa0-ad9e-65db4f040432_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:5dcbfe58-abe1-482a-8699-ca038fd56a8c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:5dcbfe58-abe1-482a-8699-ca038fd56a8c","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":22,"allele":[{"id":"cggv:3c8c4af3-6694-484b-9d92-dfc6d7f51d1b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.797dup (p.Pro266_Asn267insTer)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA214901"}},{"id":"cggv:04839883-6400-4836-94f4-388be57040c6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.1110dup (p.Val371SerfsTer3)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/209101"}}],"detectionMethod":"The article states \".....whole exome sequencing and candidate gene screening...\" but does not elaborate on whether both approaches were used in all families, or WES for some and candidate gene screening for others.","phenotypeFreeText":"Relative central scotoma.","phenotypes":"obo:HP_0007761","sex":"Male","variant":[{"id":"cggv:b0723615-34af-455a-9f90-f3f39307abb9_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:3c8c4af3-6694-484b-9d92-dfc6d7f51d1b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"},{"id":"cggv:000bc995-7d0a-4db5-a0d4-1867fb361198_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:04839883-6400-4836-94f4-388be57040c6"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"}],"rdfs:label":"CHRO436- II:1"},{"id":"cggv:000bc995-7d0a-4db5-a0d4-1867fb361198","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:000bc995-7d0a-4db5-a0d4-1867fb361198_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:b0723615-34af-455a-9f90-f3f39307abb9","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:b0723615-34af-455a-9f90-f3f39307abb9_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877_seg_el","type":"EvidenceLine","specifiedBy":"GeneValiditySegregationEvidencCriteria","strengthScore":2.5},{"id":"cggv:a2a2b5f4-3b58-4718-87fb-b0d1c113d293_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:a2a2b5f4-3b58-4718-87fb-b0d1c113d293","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":2,"allele":[{"id":"cggv:9701d29c-9ca7-4b03-abdd-df3c487429e4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.1126C>T (p.Arg376Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1214381"}},{"id":"cggv:b6ce1edd-f366-442d-8269-c949430d076a"}],"detectionMethod":"Retinal panel (no identified causal variants) followed by WES","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0006934","obo:HP_0000493","obo:HP_0008499","obo:HP_0000512","obo:HP_0007663","obo:HP_0008002"],"secondTestingMethod":"Exome sequencing","sex":"Female","variant":[{"id":"cggv:3e1ecbcc-56dd-4a8d-9c67-69f4d3d6a251_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9701d29c-9ca7-4b03-abdd-df3c487429e4"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26070061"},{"id":"cggv:4760b3fe-2e3c-43dc-8819-8bfedfd8dc50_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b6ce1edd-f366-442d-8269-c949430d076a"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26070061"}],"rdfs:label":"Xu1"},{"id":"cggv:4760b3fe-2e3c-43dc-8819-8bfedfd8dc50","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:4760b3fe-2e3c-43dc-8819-8bfedfd8dc50_variant_evidence_item"},{"id":"cggv:4760b3fe-2e3c-43dc-8819-8bfedfd8dc50_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"RT-PCR studies with the patient's blood RNA indicates that the splicing variant results in either an 83 basepair intron inclusion or exon 12 skipping and does not result in WT RNA. The mRNA products from the splice variant result in frameshift or nonsense codons that abolish ATF6 C terminal glycosylation sites. "}],"strengthScore":2},{"id":"cggv:3e1ecbcc-56dd-4a8d-9c67-69f4d3d6a251","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:3e1ecbcc-56dd-4a8d-9c67-69f4d3d6a251_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:5a007ac5-1422-4b49-a7cc-135fa2326858_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:5a007ac5-1422-4b49-a7cc-135fa2326858","type":"Proband","allele":{"id":"cggv:a6c84b18-a538-4dd2-8fdc-71de6bb7dc91","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.1018G>C (p.Ala340Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343372519"}},"firstTestingMethod":"Whole genome shotgun sequencing","sex":"Female","variant":{"id":"cggv:9f4b2056-dce1-44f4-9203-1cb15c288029_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a6c84b18-a538-4dd2-8fdc-71de6bb7dc91"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28041643","type":"dc:BibliographicResource","dc:abstract":"Inherited retinal disease is a common cause of visual impairment and represents a highly heterogeneous group of conditions. Here, we present findings from a cohort of 722 individuals with inherited retinal disease, who have had whole-genome sequencing (n = 605), whole-exome sequencing (n = 72), or both (n = 45) performed, as part of the NIHR-BioResource Rare Diseases research study. We identified pathogenic variants (single-nucleotide variants, indels, or structural variants) for 404/722 (56%) individuals. Whole-genome sequencing gives unprecedented power to detect three categories of pathogenic variants in particular: structural variants, variants in GC-rich regions, which have significantly improved coverage compared to whole-exome sequencing, and variants in non-coding regulatory regions. In addition to previously reported pathogenic regulatory variants, we have identified a previously unreported pathogenic intronic variant in CHM in two males with choroideremia. We have also identified 19 genes not previously known to be associated with inherited retinalÂ disease, which harbor biallelic predicted protein-truncating variants in unsolved cases. Whole-genome sequencing is an increasingly important comprehensive method with which to investigate the genetic causes of inherited retinal disease.","dc:creator":"Carss KJ","dc:date":"2017","dc:title":"Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease."}},"rdfs:label":"W000143"},{"id":"cggv:9f4b2056-dce1-44f4-9203-1cb15c288029","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:9f4b2056-dce1-44f4-9203-1cb15c288029_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:353884b7-6438-4d3f-8044-a10a59e3b7b1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:353884b7-6438-4d3f-8044-a10a59e3b7b1","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":16,"allele":{"id":"cggv:f4ab63cd-681b-4bbd-a962-54b5d3e3c78d"},"detectionMethod":"Haplotype analysis followed by homozygosity mapping; two candidate intervals identified; one of chromosome 1 and one on chromosome 7. The interval on chromosome 1p13.2-1q23.3 mapped within a previously identified linkage interval. WES was performed on individual II:4 to find variants within that region.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Relative central scotoma. Dark adaptation showed rod-mediated function lacking the rod-cone break and cone branch, with dark adaptation thresholds being within normal limits. Scotopic full-field electroretinography (ERG) responses were within normal limits, consistent with normal rod function, whereas photopic full-filed ERG responses were either severely reduced or no detectable, in keeping with absent or markeldly reduced cone system function.","phenotypes":"obo:HP_0007761","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:0ee7c9f6-661f-4b9d-b5c0-23736181c872_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:f4ab63cd-681b-4bbd-a962-54b5d3e3c78d"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"},"rdfs:label":"CHRO628 II:4"},{"id":"cggv:0ee7c9f6-661f-4b9d-b5c0-23736181c872","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0ee7c9f6-661f-4b9d-b5c0-23736181c872_variant_evidence_item"},{"id":"cggv:0ee7c9f6-661f-4b9d-b5c0-23736181c872_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Patient-derived fibroblasts homozygous for p.Arg324Cys had defective ATF6 transcriptional activity. "}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:0c8188c5-37df-47ab-a69c-df82dc4fa28f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:0c8188c5-37df-47ab-a69c-df82dc4fa28f","type":"Proband","allele":{"id":"cggv:b67ae609-2450-4d4c-a8d7-8c055c210b8a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.417dup (p.Asn140Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA31733964"}},"firstTestingMethod":"Whole genome shotgun sequencing","sex":"Female","variant":{"id":"cggv:e36ab45d-4d6a-427b-922b-c2a9f79c5af2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b67ae609-2450-4d4c-a8d7-8c055c210b8a"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28041643"},"rdfs:label":"G001437"},{"id":"cggv:e36ab45d-4d6a-427b-922b-c2a9f79c5af2","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:e36ab45d-4d6a-427b-922b-c2a9f79c5af2_variant_evidence_item"}],"strengthScore":1,"dc:description":"Down-scored because homozygous and no functional evidence. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:0356b959-30ad-4141-8ef4-5657bc3f27fd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:0356b959-30ad-4141-8ef4-5657bc3f27fd","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":27,"allele":{"id":"cggv:de674fd5-b1b7-4c46-b21e-4be8d9e63124","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.1187+5G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/209098"}},"detectionMethod":"The article states \".....whole exome sequencing and candidate gene screening...\" but does not elaborate on whether both approaches were used in all families, or WES for some and candidate gene screening for others.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Relative central scotoma.","phenotypes":"obo:HP_0007761","sex":"Female","variant":{"id":"cggv:14d5fbba-3b65-4b2b-80f6-9470d0f663b7_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:de674fd5-b1b7-4c46-b21e-4be8d9e63124"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"},"rdfs:label":"CHRO709- II:1"},{"id":"cggv:14d5fbba-3b65-4b2b-80f6-9470d0f663b7","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:14d5fbba-3b65-4b2b-80f6-9470d0f663b7_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:70b7152f-3e9a-48cc-8241-44df5d6d1f5a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:70b7152f-3e9a-48cc-8241-44df5d6d1f5a","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":42,"allele":{"id":"cggv:a67a1ed4-beab-4cb8-a6ac-6cb4f49c1fd2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_007348.4(ATF6):c.82+5G>T","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/209096"}},"detectionMethod":"The article states \".....whole exome sequencing and candidate gene screening...\" but does not elaborate on whether both approaches were used in all families, or WES for some and candidate gene screening for others.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"sex":"Male","variant":{"id":"cggv:96955285-c08d-4d32-849b-bd4487b5bf56_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a67a1ed4-beab-4cb8-a6ac-6cb4f49c1fd2"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"},"rdfs:label":"CHRO282- II:1"},{"id":"cggv:96955285-c08d-4d32-849b-bd4487b5bf56","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:96955285-c08d-4d32-849b-bd4487b5bf56_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f6f8a4aa-2f3e-490d-ad0e-b4c72a5aa156_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f6f8a4aa-2f3e-490d-ad0e-b4c72a5aa156","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":25,"allele":{"id":"cggv:b6ce1edd-f366-442d-8269-c949430d076a"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"sex":"Male","variant":{"id":"cggv:25f74695-8341-4c38-ba1f-4f3c35107b06_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b6ce1edd-f366-442d-8269-c949430d076a"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26029869"},"rdfs:label":"MOGL411-MOGL467 IV:1"},{"id":"cggv:25f74695-8341-4c38-ba1f-4f3c35107b06","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:25f74695-8341-4c38-ba1f-4f3c35107b06_variant_evidence_item"}],"strengthScore":1,"dc:description":"Down-scored due to homozygous variant and no functional data provided in this paper."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":4037,"specifiedBy":"GeneValidityCriteria8","strengthScore":17,"subject":{"id":"cggv:74554bce-3add-44bf-a890-81e47f70e7d5","type":"GeneValidityProposition","disease":"obo:MONDO_0100447","gene":"hgnc:791","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"ATF6 was first reported in relation to autosomal recessive early-onset retinopathy and/or achromatopsia in 2015 (Xu et al., PMID: 26070061; Kohl et al., PMID: 26029869; Ansar et al., PMID: 26063662). The term ATF6-related retinopathy is used here to describe the disease entity associated with this gene. Achromatopsia is an early-onset retinal dystrophy characterized by impaired color vision, photophobia, nystagmus, reduced visual acuity. Additional features on ocular exam include foveal hypoplasia and cone photoreceptor dysfunction. Twelve variants (missense, frameshift, nonsense, splice site) that have been reported in sixteen probands in five publications (PMIDs: 26070061, 26029869; 26063662, 28041643, 31237654) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. For example, of note, two multi-exon deletions in ATF6 were reported by Lee et al. (PMID: 32271167) as causative for autosomal recessive achromatopsia in two families, though these variants were not scored as part of this curation. The mechanism of pathogenicity is known to be loss-of-function. This gene-disease association is also supported by experimental evidence, including animal studies, expression studies, and in vitro functional assays (PMID: 26063662, 26029869, 26070061, 32271167, 28028229, 34561305). ATF6 has been shown to be expressed in mouse retina (PMID: 26070061). While wildtype ATF6 has been shown in vitro to have expression throughout the cytoplasm and localization to the ER, mutant ATF6 had significantly reduced localization in the cytoplasm (PMID: 26063662). In addition, ATF6 variants have been shown to impaired transcriptional activity in vitro (PMID: 32271167). Knockout Atf6 mice have functional deficits in photoreceptor cells (PMID: 26029869. However, the phenotype of Atf6 knock out mice does not completely recapitulate the features of human achromatopsia, as alterations in photoreceptor function are only seen at an older age in mice. Retinal organoids derived from human iPSCs with ATF6 variants are shown to have abnormal cone photoreceptor cells, lacking inner and outer segments, but typical rod photoreceptors (PMID: 34561305). In summary, ATF6 is definitively associated with autosomal recessive ATF6 retinopathy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Retina GCEP on the meeting date 10/07/2021 (SOP Version #8). This gene-disease pair was originally evaluated by the General GCEP on 11/16/2016 and reevaluated by the Retina GCEP in 2021. As a result of this reevaluation, the classification changed. The original classification was Strong and it was re-classified to Definitive due to additional genetic and experimental evidence and the demonstration of evidence for this gene-disease relationship over six years. This classification was approved by the Retina GCEP on Oct 7, 2021.\nBased on the number of points awarded.","dc:isVersionOf":{"id":"cggv:649d690a-8457-4c95-8d27-978daf4ac877"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}